1. Home
  2. SWIN vs SCYX Comparison

SWIN vs SCYX Comparison

Compare SWIN & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWIN
  • SCYX
  • Stock Information
  • Founded
  • SWIN 2017
  • SCYX 1999
  • Country
  • SWIN Hong Kong
  • SCYX United States
  • Employees
  • SWIN N/A
  • SCYX N/A
  • Industry
  • SWIN
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SWIN
  • SCYX Health Care
  • Exchange
  • SWIN Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • SWIN 32.1M
  • SCYX 28.5M
  • IPO Year
  • SWIN 2023
  • SCYX 2014
  • Fundamental
  • Price
  • SWIN $3.90
  • SCYX $0.75
  • Analyst Decision
  • SWIN
  • SCYX
  • Analyst Count
  • SWIN 0
  • SCYX 0
  • Target Price
  • SWIN N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • SWIN 274.8K
  • SCYX 116.3K
  • Earning Date
  • SWIN 08-21-2025
  • SCYX 08-07-2025
  • Dividend Yield
  • SWIN N/A
  • SCYX N/A
  • EPS Growth
  • SWIN N/A
  • SCYX N/A
  • EPS
  • SWIN N/A
  • SCYX N/A
  • Revenue
  • SWIN $3,316,000.00
  • SCYX $2,630,000.00
  • Revenue This Year
  • SWIN $29.79
  • SCYX $463.61
  • Revenue Next Year
  • SWIN $54.60
  • SCYX $310.80
  • P/E Ratio
  • SWIN N/A
  • SCYX N/A
  • Revenue Growth
  • SWIN N/A
  • SCYX N/A
  • 52 Week Low
  • SWIN $1.16
  • SCYX $0.66
  • 52 Week High
  • SWIN $3.92
  • SCYX $2.29
  • Technical
  • Relative Strength Index (RSI)
  • SWIN 83.35
  • SCYX 40.90
  • Support Level
  • SWIN $2.88
  • SCYX $0.66
  • Resistance Level
  • SWIN $3.48
  • SCYX $0.78
  • Average True Range (ATR)
  • SWIN 0.33
  • SCYX 0.05
  • MACD
  • SWIN 0.13
  • SCYX -0.00
  • Stochastic Oscillator
  • SWIN 97.22
  • SCYX 34.32

About SWIN Solowin Holdings

Solowin Holdings Ltd is a investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secured one-stop electronic platform. It is engaged in providing securities related services, investment advisory service, and asset management service to customers. The operations were organized into four reportable segments: securities related services, investment advisory services, corporate consultancy services, and asset management services. It derives maximum revenue from investment advisory services.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: